



European Investment Bank (EIB)

Luxembourg, 21 December 2022

## Environmental and Social Completion Sheet (ESCS)

### Overview

Project Name: Newron (EGFF)

Project Number: 2017-0788

Country: Italy

Project Description: *The investment program consisted of the discovery, pre-clinical and clinical development of a portfolio of assets, addressing different therapeutic areas focusing on underserved neurological conditions. The candidates are at various developmental stages.*

### Summary of Environmental and Social Assessment at Completion

The project covered the promoter's investments in research, development and innovation activities in the pharmaceutical and biotechnology sectors, enabling the company to advance its portfolio of promising and diverse medicinal product candidates along the development value chain. The project's activities are not listed in any of the annexes of the EU Directive 2014/52/EU amending 2011/92/EU. The project was carried out in existing facilities already authorised for similar activities and volumes.

The promoter's R&D practices are in compliance with relevant national and EU legislation (directives 2001/83EC, 2005/28/EC, 2001/20/EC and Good Clinical Practice, as applicable) and the promoter maintains adequate internal procedures and management practices.

The project has been performed according to state-of-the-art technology and has taken into consideration environmentally friendly, low energy-and-resource consuming technologies.

#### Summary opinion of Environmental and Social aspects at completion:

EIB is of the opinion based on the above, that the Project has been implemented in line with EIB Environmental and Social Standards, applicable at the time of appraisal.